Number of pages: 100 | Report Format: PDF | Published date: April 10, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
According to the deep-dive market assessment study by Growth Plus Reports, the global osteomyelitis therapeutics market was valued at US$ 1.50 billion in 2022 and is expected to register a revenue CAGR of 7.09% to reach US$ 2.78 billion by 2031.
Osteomyelitis Therapeutics Market Fundamentals
Bone infection, also known as osteomyelitis, is a rare illness that can spread through a number of pathways, including the bloodstream, bone exposure to an infected environment following surgery or injury, and other related circumstances. A form of bacteria known as staphylococcus aureus commonly causes bone infections. Diabetes, which causes wounds to heal more slowly than usual, has been linked to an increase in the probability of a bone infection. A bone infection can occur at any age, although it is more frequent in those with weakened immune systems, such as those with diabetes, HIV, sickle cell disease, rheumatoid arthritis, or on hemodialysis, among other disorders.
The Osteomyelitis therapeutics market is estimated to show notable growth during the forecast period of 2023 to 2031. The global osteomyelitis therapeutics industry trends are increasing the incidence of osteomyelitis, rapidly growing demand for advanced treatment methods, growing awareness about the available treatment options for osteomyelitis, technological advancements, availability of government funding, and support for research on bone infections treatment. This report provides the global osteomyelitis market analysis in terms of revenue, market growth, market dynamics, regional landscape, and overall competitive positioning of the major market players.
Osteomyelitis Therapeutics Market Dynamics
The trend of patients increasingly preferring non-invasive and minimally invasive surgical procedures is driving the market revenue expansion. Because of the various advantages they provide over traditional treatment methods, there is substantial revenue growth in demand for minimally invasive therapy treatments. Minimally invasive therapies have low setbacks during surgery, shorter hospital stays, lower levels of pain and suffering, smaller and less apparent incisions, a lower risk of infection, less need for postoperative care, and a faster pace of recovery. Minimally invasive therapies employ cutting-edge technology to detect and treat a wide range of illnesses and ailments, including cancer. Rising R&D efforts by pharmaceutical and biopharmaceutical organizations to identify innovative therapeutics for bone infection treatment are expected to push the market for bone infection treatments even more. It is expected that regulatory agencies will take a favorable drug development and approval approach, resulting in a rise in the number of molecules in the pipeline for the treatment of bone infections, which will fuel the expansion of the market for bone infection therapies.
However, some restraining factors can hamper the global market revenue growth. The high cost of treatment and osteomyelitis drugs may impede the market expansion rate. Osteomyelitis pharmaceutical companies will experience difficulties due to a lack of qualified professionals and healthcare infrastructure in underdeveloped countries.
Osteomyelitis Therapeutics Market Ecosystem
The global osteomyelitis therapeutics market is analyzed from six perspectives: type, patient type, treatment, route of administration, distribution channel, and region.
Osteomyelitis Therapeutics Market by Type
Based on the type, the global osteomyelitis therapeutics market is segmented into acute, chronic, and vertebral.
The chronic osteomyelitis segment accounts for a prominent revenue share in the global market, ascribing to the growing cases of hematogenous (blood-borne) osteomyelitis, anaerobic osteomyelitis, and pyogenic osteomyelitis. Chronic osteomyelitis generally develops after acute osteomyelitis and is occasionally linked with a draining sinus tract. The impacted site may experience bone pain, edema, redness, and tenderness. The initial sign is frequently a flow of pus from an entrance to the affected bone. There may also be bone destruction, with a section of diseased bone separating from good bone. Thus, resulting in the growing need for advanced osteomyelitis treatments.
Similarly, the vertebral osteomyelitis segment is expected to grow significantly in terms of revenue share during the forecast period. Spinal infections, or spinal/vertebral osteomyelitis, are usually transmitted through the bloodstream or appear as post-surgical sequelae. These spinal infections are frequently characterized by chronic back pain that does not respond to traditional treatment, such as bed rest, heat, or pain medications. Fever, localized discomfort, pain, muscular spasms, and restricted mobility are all possible symptoms. If a patient has a known fever, weight loss, bacteremia, or endocarditis and has new or increased back pain, they should be referred for a spinal MRI. This type of osteomyelitis typically affects adults over 50 and is caused by a prior injury, urinary tract infection, inflammation of the heart lining (endocarditis), or drug addiction. All these factors contribute to the growth of the vertebral osteomyelitis segment, thereby propelling the global market revenue growth.
Osteomyelitis Therapeutics Market by Patient Type
Based on the patient type, the global osteomyelitis therapeutics market is segmented into adults and pediatrics.
The adult segment dominates the global market with the largest revenue share. Adults are more likely to develop osteomyelitis due to various risk factors, such as diabetes, intravenous drug use, surgery, and trauma. Additionally, the treatment of osteomyelitis in adults can also differ from that in children, as adults may suffer from more complex cases and comorbidities that require more extensive and aggressive treatment.
Osteomyelitis Therapeutics Market by Treatment
Based on the treatment, the global osteomyelitis therapeutics market is segmented into antibiotics, antifungals, and analgesics.
The antibiotics segment registered the largest revenue share in the global market in 2022. The antibiotics segment dominates the global osteomyelitis therapeutics market because antibiotics are the primary treatment in most cases. Osteomyelitis is a bacterial infection that affects the bone and surrounding tissues, and antibiotics are the most effective way to kill the bacteria causing the infection. Antibiotics are often combined with surgical intervention, such as debridement or bone grafting, to treat osteomyelitis effectively. Antibiotics can help prevent the spread of infection, reduce inflammation, and promote healing of the affected bone and tissue. Several antibiotics can treat osteomyelitis, including penicillin, cephalosporins, fluoroquinolones, aminoglycosides, and others. The choice of antibiotic depends on the type of bacteria causing the infection, as well as the patient's age, medical history, and other factors.
Osteomyelitis Therapeutics Market by Route of Administration
Based on the route of administration, the global osteomyelitis therapeutics market is segmented into parenteral, topical, and oral.
The oral segment dominates the global osteomyelitis therapeutics market because oral antibiotics are often the first-line treatment for osteomyelitis. Oral antibiotics are convenient, non-invasive, and can be administered at home, which is especially beneficial for patients with chronic or recurrent osteomyelitis. In addition, oral antibiotics are effective in treating mild to moderate cases of osteomyelitis, where the infection is localized and has reduced the spread extensively. Oral antibiotics can help prevent the spread of infection, reduce inflammation, and promote healing of the affected bone and tissue. Furthermore, oral antibiotics are generally less expensive than intravenous (IV) antibiotics and require less frequent administration, which can lead to improved patient compliance and lower healthcare costs. Moreover, intravenous antibiotics may be necessary for more severe cases of osteomyelitis, or when oral antibiotics are not effective, the widespread availability and use of effective oral antibiotics have made them the preferred treatment option for many patients and healthcare providers.
Osteomyelitis Therapeutics Market by Distribution Channel
Based on the distribution channel, the global osteomyelitis therapeutics market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
The hospital pharmacies segment dominates the global osteomyelitis therapeutics market in terms of revenue share due to hospitals being often the primary site of care for patients with osteomyelitis. Patients with osteomyelitis typically require hospitalization for treatment, including administering antibiotics and, in some cases, surgical intervention. Hospital pharmacies are responsible for dispensing medications to patients in the hospital setting and post-discharge, including antibiotics and other medications used to treat osteomyelitis. Hospital pharmacies also play a critical role in ensuring that medications are administered safely and effectively and that dosages are adjusted as needed based on patient response. In addition, hospitals often have more resources and expertise available to manage complex cases of osteomyelitis, which may require a multidisciplinary team of healthcare providers. This can include infectious disease specialists, orthopedic surgeons, and other specialists who work together to provide comprehensive care for patients with osteomyelitis.
Osteomyelitis Therapeutics Market by Region
Based on the region, the global osteomyelitis therapeutics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America has a relatively high prevalence of osteomyelitis. North America has a well-developed healthcare infrastructure, including hospitals and medical centers with the resources and expertise to manage complex cases of osteomyelitis. This allows for early detection and prompt treatment, reducing the risk of complications and improving patient outcomes. Favorable reimbursement policies for treating osteomyelitis support the healthcare system in North America. This provides financial incentives for healthcare providers to deliver high-quality care and ensure patients receive the necessary treatment to manage their condition. North America is home to several key market players in the osteomyelitis therapeutics market, including pharmaceutical companies, medical device manufacturers, and healthcare providers. This has led to the development of innovative products and treatments for osteomyelitis, which has contributed to the segment's revenue growth.
Competitive Landscape of the Global Osteomyelitis Therapeutics Market
The prominent players operating in the global osteomyelitis therapeutics market are:
Strategic Developments in Osteomyelitis Therapeutics Market
The global osteomyelitis therapeutics market was valued at US$ 1.50 billion in 2022.
The chronic osteomyelitis segment dominates the global osteomyelitis therapeutics market with the largest revenue share.
The expected size of the global osteomyelitis therapeutics market in 2031 is US$ 2.78 billion.
The rise in osteomyelitis cases and the growing focus on developing advanced technologies drive the revenue growth of the global market.
The market players in the global osteomyelitis therapeutics market are Sanofi S.A., Pfizer Inc., Novartis AG, and Mylan N.V., among others.
*Insights on financial performance are subject to the availability of information in the public domain